Know Cancer

or
forgot password

A Groupwide Randomized Phase II Window Study of Two Different Schedules of Irinotecan in Combination With Vincristine And Pilot Assessment of Safety and Efficacy of Tirapazamine Combined With Multiagent Chemotherapy for First Relapse or Progressive Disease in Rhabdomyosarcoma and Related Tumors


Phase 2
N/A
20 Years
Not Enrolling
Both
Alveolar Childhood Rhabdomyosarcoma, Embryonal Childhood Rhabdomyosarcoma, Embryonal-botryoid Childhood Rhabdomyosarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Rhabdomyosarcoma

Thank you

Trial Information

A Groupwide Randomized Phase II Window Study of Two Different Schedules of Irinotecan in Combination With Vincristine And Pilot Assessment of Safety and Efficacy of Tirapazamine Combined With Multiagent Chemotherapy for First Relapse or Progressive Disease in Rhabdomyosarcoma and Related Tumors


OBJECTIVES:

I. Compare response rate in children with relapsed or progressive rhabdomyosarcoma,
undifferentiated sarcoma, or ectomesenchymoma treated with 2 different schedules of
irinotecan and vincristine in an upfront phase II window.

II. Determine the progression-free and overall survival of patients treated with multiagent
chemotherapy.

III. Determine the toxic effects of tirapazamine, doxorubicin, and cyclophosphamide in these
patients.

IV. Determine the toxic effects of irinotecan and vincristine in these patients.

V. Determine whether conversion of irinotecan to its active metabolite SN-38 predicts tumor
response in these patients.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to risk
status and window therapy eligibility (unfavorable risk and eligible vs unfavorable risk and
ineligible vs favorable risk).

UNFAVORABLE-RISK PATIENTS ELIGIBLE FOR WINDOW THERAPY: Patients are stratified according to
prior topotecan (yes vs no). These patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive vincristine IV on days 1 and 8 and irinotecan IV over 1 hour on days
1-5 and 8-12. Treatment repeats every 21 days for 2 courses in the absence of disease
progression or unacceptable toxicity.

ARM II: Patients receive vincristine IV on days 1 and 8 and irinotecan IV over 1 hour on
days 1-5. Treatment repeats every 21 days for 2 courses in the absence of disease
progression or unacceptable toxicity.

Patients in both arms with partial response (PR) or complete response (CR) receive 5
additional courses of irinotecan and vincristine on the previous schedule. In addition,
patients with PR or CR also receive cyclophosphamide/doxorubicin (CD) and
ifosfamide/etoposide (IE) chemotherapy.

CD/IE CHEMOTHERAPY: Patients receive cyclophosphamide IV over 1 hour and doxorubicin IV
over 15-30 minutes on day 1 of weeks 7, 16, 28, 37, and 40. Patients also receive ifosfamide
IV over 1 hour and etoposide IV over 1 hour on days 1-5 of weeks 10, 19, 22, 31, and 43.
Treatment continues in the absence of disease progression or unacceptable toxicity.

Patients with no response or progressive disease on arm I or II proceed to
tirapazamine/cyclophosphamide/doxorubicin (TCD) and ifosfamide/etoposide (IE) chemotherapy.

TCD/IE CHEMOTHERAPY: Patients receive tirapazamine IV over 2 hours, cyclophosphamide IV over
1 hour, and doxorubicin IV over 15-30 minutes on day 1 of weeks 7, 10, 16, 25, and 34.
Patients also receive ifosfamide IV over 1 hour and etoposide IV over 1 hour on days 1-5 of
weeks 13, 19, 22, 28, 31, and 37.

PATIENTS WITH UNFAVORABLE RISK AND INELIGIBLE FOR WINDOW THERAPY: Patients receive
tirapazamine IV over 2 hours, cyclophosphamide IV over 1 hour, and doxorubicin IV over 15-30
minutes on day 1 of weeks 1, 4, 10, 19, and 28. Patients also receive ifosfamide IV over 1
hour and etoposide IV over 1 hour on days 1-5 of weeks 7, 13, 16, 22, 25, and 31. Patients
also receive filgrastim (G-CSF) or sargramostim (GM-CSF) subcutaneously (SC) beginning 1 day
after each course of chemotherapy and continuing until blood counts recover. Treatment
continues in the absence of disease progression or unacceptable toxicity.

PATIENTS WITH FAVORABLE RISK: Patients receive cyclophosphamide IV over 1 hour and
doxorubicin IV over 15-30 minutes on day 1 of weeks 1, 4, 10, 19, and 28. Patients also
receive ifosfamide IV over 1 hour and etoposide IV over 1 hour on days 1-5 of weeks 7, 13,
16, 22, 25, and 31. Patients also receive G-CSF or GM-CSF SC beginning 1 day after each
course of chemotherapy and continuing until blood counts recover. Treatment continues in the
absence of disease progression or unacceptable toxicity.

Patients are followed every 2 months for 1 year, every 4 months for 2 years, and then
annually thereafter.


Inclusion Criteria:



- Histologically confirmed rhabdomyosarcoma, undifferentiated sarcoma, or
ectomesenchymoma

- First relapse or first occurrence of disease progression

- Unfavorable-risk patients eligible for study window therapy with irinotecan and
vincristine meeting the following criteria:

- Unfavorable risk defined by any of the following:

- Embryonal histology with stage I or group I at initial diagnosis with
distant recurrence or with local or regional recurrence after prior
cyclophosphamide

- Embryonal histology with initial stage II, III, or IV or group II, III, or
IV with any relapse pattern

- Alveolar histology with any stage or group at initial diagnosis

- At least unidimensionally measurable disease

- No prior irinotecan

- Bone marrow must not be only site of relapse

- Unfavorable-risk patients ineligible for study window therapy with irinotecan meeting
the following criteria:

- Either no measurable disease OR patient received prior irinotecan

- Bone marrow as only site of relapse allowed

- Favorable-risk patients meeting the following criteria:

- Initial botryoid histology (any stage, any group, or any pattern of relapse)

- Embryonal histology if either stage I or group I (with either local or regional
recurrence)

- No prior cyclophosphamide

- No CNS metastases

- Performance status - ECOG 0-2

- Performance status - Zubrod 0-2

- At least 2 months

- Absolute neutrophil count at least 750/mm^3

- Platelet count at least 75,000/mm^3 (transfusion independent)

- Hemoglobin at least 10.0 g/dL (red blood cell transfusion allowed)

- Bilirubin no greater than 1.5 times normal

- SGPT less than 2.5 times normal

- Creatinine no greater than 1.5 times normal

- Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min

- Shortening fraction at least 27% by echocardiogram

- Ejection fraction at least 50% by MUGA

- No prior ischemic heart disease

- Seizure disorder allowed if well controlled by anticonvulsants

- No CNS toxicity greater than grade 2

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No prior myeloablative therapy with stem cell transplantation

- At least 1 week since prior antineoplastic biologic agent

- At least 1 week since prior growth factor(s)

- Recovered from prior immunotherapy

- No concurrent immunomodulating agents

- See Disease Characteristics

- See Biologic therapy

- No more than 1 prior chemotherapy regimen

- No prior doxorubicin or daunorubicin

- At least 2 weeks since prior myelosuppressive chemotherapy (4 weeks for nitrosoureas)
and recovered

- No other concurrent anticancer chemotherapy

- Concurrent corticosteroid therapy allowed

- At least 2 weeks since prior small-port radiotherapy.

- At least 6 months since prior radiotherapy to 50% or more of pelvis

- At least 6 weeks since other prior substantial radiotherapy to bone marrow

- Recovered from prior radiotherapy

- Concurrent radiotherapy to localized painful lesions allowed provided at least 1
measurable lesion is not irradiated

- No concurrent intensity-modulated radiotherapy

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Response at week 6 of investigational window therapy (unfavorable risk patients)

Outcome Time Frame:

At week 6

Safety Issue:

No

Principal Investigator

Philip Breitfeld

Investigator Role:

Principal Investigator

Investigator Affiliation:

Children's Oncology Group

Authority:

United States: Food and Drug Administration

Study ID:

NCI-2012-01864

NCT ID:

NCT00025363

Start Date:

November 2001

Completion Date:

Related Keywords:

  • Alveolar Childhood Rhabdomyosarcoma
  • Embryonal Childhood Rhabdomyosarcoma
  • Embryonal-botryoid Childhood Rhabdomyosarcoma
  • Previously Treated Childhood Rhabdomyosarcoma
  • Recurrent Childhood Rhabdomyosarcoma
  • Rhabdomyosarcoma
  • Rhabdomyosarcoma, Embryonal

Name

Location

Children's Oncology GroupArcadia, California  91006-3776